| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 18,692 | 24,287 | ||
| Accounts receivable, net of allowance for credit losses of 3 and 16, respectively | 258 | 512 | ||
| Inventories | 471 | 693 | ||
| Restricted cash, current | 729 | - | ||
| Prepaid expenses and other current assets | 1,239 | 1,350 | ||
| Total current assets | 21,389 | 26,842 | ||
| Right-of-use and financing lease assets, net | 2,340 | 2,524 | ||
| Machinery and equipment, net, and construction in progress | 4,147 | 4,149 | ||
| Intangible assets, net | 14,600 | 14,600 | ||
| Restricted cash, noncurrent | 789 | 1,700 | ||
| Other noncurrent assets | 672 | 702 | ||
| Total assets | 43,937 | 50,517 | ||
| Accounts payable | 1,056 | 1,277 | ||
| Accrued compensation | 2,228 | 1,459 | ||
| Accrued royalties | 1,120 | 1,116 | ||
| Accrued expenses and other current liabilities | 602 | 571 | ||
| Right-of-use and financing lease liabilities, current | 1,598 | 1,540 | ||
| Contingent consideration liabilities, current | 1,056 | 689 | ||
| Total current liabilities | 7,660 | 6,652 | ||
| Right-of-use and financing lease liabilities, noncurrent | 1,529 | 1,834 | ||
| Contingent consideration liabilities, noncurrent | 43,944 | 40,933 | ||
| Preferred stock, no par value, 5,000 shares authorized no shares issued and outstanding | - | 0 | ||
| Total liabilities | 53,133 | 49,419 | ||
| Common stock, no par value, 230,000 shares authorized 28,625 and 17,453 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 368,524 | 367,965 | ||
| Accumulated other comprehensive income | 86 | 85 | ||
| Accumulated deficit | -377,806 | -366,952 | ||
| Total shareholders' deficit | -9,196 | 1,098 | ||
| Total liabilities and shareholders' deficit | 43,937 | 50,517 | ||
Insight Molecular Diagnostics Inc. (IMDX)
Insight Molecular Diagnostics Inc. (IMDX)